BioCentury | Nov 1, 2019
Product Development

Adrenomed looks beyond immune modulators for sepsis, aims for shock prevention

By targeting a new mechanism further downstream in the sepsis pathway than previous approaches, Adrenomed thinks it can escape the graveyard that has sunk drug development in the indication. Its approach hinges on preventing the...
BioCentury | Apr 13, 2018
Clinical News

Patient deaths reported in Tecentriq, Cotellic combo arm of Phase II mCRC trial

Roche (SIX:ROG; OTCQX:RHHBY) said it temporarily halted recruitment in the Phase II MODUL trial to treat metastatic colorectal cancer (mCRC) following four deaths, including a case of treatment-related cardiogenic shock, in a cohort of patients...
BioCentury | Apr 10, 2018
Clinical News

Patient deaths reported in Tecentriq, Cotellic combo arm of mCRC trial

Roche (SIX:ROG; OTCQX:RHHBY) said it temporarily halted recruitment in the Phase II MODUL trial to treat metastatic colorectal cancer following four deaths, including a case of treatment-related cardiogenic shock, in a cohort of patients receiving...
BioCentury | Oct 14, 2015
Financial News

Audentes raises $65 million in series C

Gene therapy company Audentes Therapeutics Inc. (San Francisco, Calif.) raised $65 million in a series C round co-led by existing investor Sofinnova Ventures and new investor Redmile Group. New investors RA Capital; T. Rowe Price;...
BioCentury | Oct 5, 2015
Company News

Cadiogen, Audentes Therapeutics deal

Audentes acquired fellow rare disease company Cardiogen for an undisclosed amount. Audentes gains AT003 (formerly CASQ2-CPVT ), a preclinical adeno-associated virus (AAV) vector-based therapy that delivers calsequestrin 2 (CASQ2) to cardiomyocytes to treat catecholaminergic polymorphic...
BioCentury | Nov 24, 2014
Clinical News

LB1148 regulatory update

Leading BioSciences submitted a compassionate use IND to FDA for LB1148 to treat gastrointestinal breakdown and multi-organ failure resulting from Ebola infection. The company plans to begin 2 Phase II trials early next year of...
BioCentury | Jun 23, 2014
Financial News

CardioGenics completes private placement

CardioGenics Holdings Inc. (OTCBB:CGNHE), Mississauga, Ontario Business: Diagnostic Date completed: 2014-06-12 Type: Private placement Raised: $1.3 million Shares: 12 million Price: $0.11 Shares after offering: 48.9 million Note: CardioGenics shares are expected to begin trading...
BioCentury | Mar 11, 2013
Company News

Cardiome, Merck deal

Cardiome paid former partner Merck the final $13 million under a December agreement to pay the pharma $20 million by March 31, 2013, to settle $50 million in debt obligations under an amended 2009 deal...
BioCentury | Dec 24, 2012
Company News

Cardiome, Merck deal

Cardiome agreed to pay former partner Merck $20 million by March 31, 2013, to settle $50 million in debt obligations under an amended 2009 deal to develop and commercialize IV and oral formulations of atrial...
BioCentury | Oct 1, 2012
Company News

Cardiome, Merck deal

Merck will return all rights to develop and commercialize IV and oral formulations of atrial fibrillation (AF) product vernakalant to partner Cardiome, terminating an amended 2009 deal to develop and commercialize both formulations. The pharma...
Items per page:
1 - 10 of 77
BioCentury | Nov 1, 2019
Product Development

Adrenomed looks beyond immune modulators for sepsis, aims for shock prevention

By targeting a new mechanism further downstream in the sepsis pathway than previous approaches, Adrenomed thinks it can escape the graveyard that has sunk drug development in the indication. Its approach hinges on preventing the...
BioCentury | Apr 13, 2018
Clinical News

Patient deaths reported in Tecentriq, Cotellic combo arm of Phase II mCRC trial

Roche (SIX:ROG; OTCQX:RHHBY) said it temporarily halted recruitment in the Phase II MODUL trial to treat metastatic colorectal cancer (mCRC) following four deaths, including a case of treatment-related cardiogenic shock, in a cohort of patients...
BioCentury | Apr 10, 2018
Clinical News

Patient deaths reported in Tecentriq, Cotellic combo arm of mCRC trial

Roche (SIX:ROG; OTCQX:RHHBY) said it temporarily halted recruitment in the Phase II MODUL trial to treat metastatic colorectal cancer following four deaths, including a case of treatment-related cardiogenic shock, in a cohort of patients receiving...
BioCentury | Oct 14, 2015
Financial News

Audentes raises $65 million in series C

Gene therapy company Audentes Therapeutics Inc. (San Francisco, Calif.) raised $65 million in a series C round co-led by existing investor Sofinnova Ventures and new investor Redmile Group. New investors RA Capital; T. Rowe Price;...
BioCentury | Oct 5, 2015
Company News

Cadiogen, Audentes Therapeutics deal

Audentes acquired fellow rare disease company Cardiogen for an undisclosed amount. Audentes gains AT003 (formerly CASQ2-CPVT ), a preclinical adeno-associated virus (AAV) vector-based therapy that delivers calsequestrin 2 (CASQ2) to cardiomyocytes to treat catecholaminergic polymorphic...
BioCentury | Nov 24, 2014
Clinical News

LB1148 regulatory update

Leading BioSciences submitted a compassionate use IND to FDA for LB1148 to treat gastrointestinal breakdown and multi-organ failure resulting from Ebola infection. The company plans to begin 2 Phase II trials early next year of...
BioCentury | Jun 23, 2014
Financial News

CardioGenics completes private placement

CardioGenics Holdings Inc. (OTCBB:CGNHE), Mississauga, Ontario Business: Diagnostic Date completed: 2014-06-12 Type: Private placement Raised: $1.3 million Shares: 12 million Price: $0.11 Shares after offering: 48.9 million Note: CardioGenics shares are expected to begin trading...
BioCentury | Mar 11, 2013
Company News

Cardiome, Merck deal

Cardiome paid former partner Merck the final $13 million under a December agreement to pay the pharma $20 million by March 31, 2013, to settle $50 million in debt obligations under an amended 2009 deal...
BioCentury | Dec 24, 2012
Company News

Cardiome, Merck deal

Cardiome agreed to pay former partner Merck $20 million by March 31, 2013, to settle $50 million in debt obligations under an amended 2009 deal to develop and commercialize IV and oral formulations of atrial...
BioCentury | Oct 1, 2012
Company News

Cardiome, Merck deal

Merck will return all rights to develop and commercialize IV and oral formulations of atrial fibrillation (AF) product vernakalant to partner Cardiome, terminating an amended 2009 deal to develop and commercialize both formulations. The pharma...
Items per page:
1 - 10 of 77